Navigating the prime editing strategy to treat cardiovascular genetic disorders in transforming heart health

References

• Sherkow JS, Zettler PJ, Greely HT. Is it ‘gene therapy’? J Law Biosci. 2018;5(3):786–793. doi: 10.1093/jlb/lsy020
   PubMed Web of Science ®Google Scholar
• Anguela XM, High KA Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–288. 1 doi: 10.1146/annurev-med-012017-043332
   PubMed Web of Science ®Google Scholar
• Tamura R, Toda M. Historic overview of genetic engineering technologies for human gene therapy. Neurol Med Chir (Tokyo). 2020;60(10):483–491. doi: 10.2176/nmc.ra.2020-0049
   PubMed Web of Science ®Google Scholar
• Sun N, Zhao H. Transcription activator-like effector nucleases (TALENs): a highly efficient and versatile tool for genome editing. Biotechnol Bioengineering. 2013;110(7):1811–1821. doi: 10.1002/bit.24890
   PubMed Web of Science ®Google Scholar
• Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636–646. doi: 10.1038/nrg2842
   PubMed Web of Science ®Google Scholar
• Schenkwein D, Afzal S, Nousiainen A, et al. Efficient nuclease-directed integration of lentivirus vectors into the human ribosomal DNA locus. Mol Ther. 2020;28(8):1858–1875. doi: 10.1016/j.ymthe.2020.05.019
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (1979). 2012;337(6096):816–821. doi: 10.1126/science.1225829
   PubMed Web of Science ®Google Scholar
• Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011;471(7340):602–607. doi: 10.1038/nature09886
   PubMed Web of Science ®Google Scholar
• Marraffini LA, Sontheimer EJ CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Sci (1979). 2008;322(5909):1843–1845. doi: 10.1126/science.1165771
   PubMed Web of Science ®Google Scholar
• Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science (1979). 2007;315(5819):1709–1712. doi: 10.1126/science.1138140
   PubMed Web of Science ®Google Scholar
• Zhang F, Wen Y, Guo X CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014;23(R1):R40–R46. doi: 10.1093/hmg/ddu125
   PubMed Web of Science ®Google Scholar
• Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnol. 2014;32(4):347–355. doi: 10.1038/nbt.2842
   PubMed Web of Science ®Google Scholar
• Pickar-Oliver A, Gersbach CA. The next generation of CRISPR–cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490–507. doi: 10.1038/s41580-019-0131-5
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR–cas nucleases, base editors, transposases and prime editors. Nature Biotechnol. 2020;38(7):824–844. doi: 10.1038/s41587-020-0561-9
   PubMed Web of Science ®Google Scholar
• Wu X, Kriz AJ, Sharp PA Target specificity of the CRISPR-Cas9 system. Quant Biol. 2014;2:59–70. 2 doi: 10.1007/s40484-014-0030-x
   PubMedGoogle Scholar
• van Overbeek M, Capurso D, Carter MM, et al. DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks. Mol Cell. 2016;63(4):633–646. doi: 10.1016/j.molcel.2016.06.037
   PubMed Web of Science ®Google Scholar
• Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181–211. 1 doi: 10.1146/annurev.biochem.052308.093131
   PubMedGoogle Scholar
• Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol. 1994;14(12):8096–8106. doi: 10.1128/MCB.14.12.8096
   PubMed Web of Science ®Google Scholar
• Rouet P, Smih F, Jasin M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Nat Acad Sci. 1994;91(13):6064–6068. doi: 10.1073/pnas.91.13.6064
   PubMed Web of Science ®Google Scholar
• Dong Y, Peng T, Wu W, et al. Efficient introduction of an isogenic homozygous mutation to induced pluripotent stem cells from a hereditary hearing loss family using CRISPR/Cas9 and single-stranded donor oligonucleotides. J Int Med Res. 2019;47(4):1717–1730. doi: 10.1177/0300060519829990
   PubMed Web of Science ®Google Scholar
• Sakuno T, Hiraoka Y. Rec8 Cohesin: a structural platform for shaping the meiotic chromosomes. Genes (Basel). 2022;13(2):200. doi: 10.3390/genes13020200
   PubMed Web of Science ®Google Scholar
• Komor AC, Badran AH, Liu DR. CRISPR-Based technologies for the manipulation of eukaryotic genomes. Cell. 2017;168(1):20–36. doi: 10.1016/j.cell.2016.10.044
   PubMed Web of Science ®Google Scholar
• Gaudelli NM, Komor AC, Rees HA, et al. Programmable base editing of T to G C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464–471. doi: 10.1038/nature24644
   PubMed Web of Science ®Google Scholar
• Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420–424. doi: 10.1038/nature17946
   PubMed Web of Science ®Google Scholar
• Sakuma T, Nakade S, Sakane Y, et al. MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nat Protoc. 2016;11(1):118–133. doi: 10.1038/nprot.2015.140
   PubMed Web of Science ®Google Scholar
• Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. Nature Biotechnol. 2018;36(8):765–771. doi: 10.1038/nbt.4192
   PubMed Web of Science ®Google Scholar
• Alanis-Lobato G, Zohren J, McCarthy A, et al. Frequent loss of heterozygosity in CRISPR-Cas9–edited early human embryos. Proc Natl Acad Sci, USA. 2021;118(22). doi: 10.1073/pnas.2004832117
   PubMed Web of Science ®Google Scholar
• Tao J, Wang Q, Mendez-Dorantes C, et al. Frequency and mechanisms of LINE-1 retrotransposon insertions at CRISPR/Cas9 sites. Nat Commun. 2022;13(1):3685. doi: 10.1038/s41467-022-31322-3
   PubMed Web of Science ®Google Scholar
• Ihry RJ, Worringer KA, Salick MR, et al. P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nature Med. 2018;24(7):939–946. doi: 10.1038/s41591-018-0050-6
   PubMed Web of Science ®Google Scholar
• Haapaniemi E, Botla S, Persson J, et al. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nature Med. 2018;24(7):927–930. doi: 10.1038/s41591-018-0049-z
   PubMed Web of Science ®Google Scholar
• Enache OM, Rendo V, Abdusamad M, et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nature Genet. 2020;52(7):662–668. doi: 10.1038/s41588-020-0623-4
   PubMed Web of Science ®Google Scholar
• Song Y, Liu Z, Zhang Y, et al. Large-fragment deletions induced by Cas9 cleavage while not in the BEs system. Mol Ther Nucleic Acids. 2020;21:523–526. doi: 10.1016/j.omtn.2020.06.019
   PubMedGoogle Scholar
• Ferrari S, Jacob A, Beretta S, et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nature Biotechnol. 2020;38(11):1298–1308. doi: 10.1038/s41587-020-0551-y
   PubMed Web of Science ®Google Scholar
• Yang L, Briggs AW, Chew WL, et al. Engineering and optimising deaminase fusions for genome editing. Nat Commun. 2016;7(1):13330. doi: 10.1038/ncomms13330
   PubMedGoogle Scholar
• Cho SI, Lee S, Mok YG, et al. Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases. Cell. 2022;185(10):1764–1776. doi: 10.1016/j.cell.2022.03.039
   PubMed Web of Science ®Google Scholar
• Mok BY, de Moraes MH, Zeng J, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020;583(7817):631–637. doi: 10.1038/s41586-020-2477-4
   PubMed Web of Science ®Google Scholar
• Nishida K, Arazoe T, Yachie N, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Sci (1979). 2016;353(6305):aaf8729. doi: 10.1126/science.aaf8729
   PubMed Web of Science ®Google Scholar
• Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia- associated mutations from background genetic noise. J Am Coll Cardiol. 2011;57(23):2317–2327. doi: 10.1016/j.jacc.2010.12.036
   PubMed Web of Science ®Google Scholar
• Van Der Zwaag PA, Jongbloed JDH, Van Den Berg MP, et al. A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. Hum Mutat. 2009;30(9):1278–1283. doi: 10.1002/humu.21064
   PubMed Web of Science ®Google Scholar
• Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121(13):1533–1541. doi: 10.1161/CIRCULATIONAHA.108.840827
   PubMed Web of Science ®Google Scholar
• Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16(11):e301–e372. doi: 10.1016/j.hrthm.2019.05.007
   PubMed Web of Science ®Google Scholar
• Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the heart rhythm society (HRS) and the European heart rhythm association (EHRA). Heart Rhythm. 2011;8(8):1308–1339. doi: 10.1016/j.hrthm.2011.05.020
   PubMed Web of Science ®Google Scholar
• Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68(21):2299–2307. doi: 10.1016/j.jacc.2016.08.058
   PubMed Web of Science ®Google Scholar
• Ware JS, Cook SA. Role of titin in cardiomyopathy: from DNA variants to patient stratification. Nat Rev Cardiol. 2018;15(4):241–252. doi: 10.1038/nrcardio.2017.190
   PubMed Web of Science ®Google Scholar
• Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619–628. doi: 10.1056/NEJMoa1110186
   PubMed Web of Science ®Google Scholar
• Walsh R, Thomson KL, Ware JS, et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet Med. 2017;19(2):192–203. doi: 10.1038/gim.2016.90
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531–547. doi: 10.1038/nrcardio.2013.105
   PubMed Web of Science ®Google Scholar
• Ingles J, Burns C, Bagnall RD, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circulation. 2017;10(2):e001620. doi: 10.1161/CIRCGENETICS.116.001620
   PubMed Web of Science ®Google Scholar
• Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12(2):e002460. doi: 10.1161/CIRCGEN.119.002460
   PubMed Web of Science ®Google Scholar
• Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705–715. doi: 10.1016/j.jacc.2012.02.068
   PubMed Web of Science ®Google Scholar
• Sedaghat-Hamedani F, Haas J, Zhu F, et al. Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy. Eur Heart J. 2017;38(46):3449–3460. doi: 10.1093/eurheartj/ehx545
   PubMed Web of Science ®Google Scholar
• Zhang J, Han X, Lu Q, et al. Left ventricular non-compaction cardiomyopathy associated with the PRKAG2 mutation. BMC Med Genomics. 2022;15(1):1–8. doi: 10.1186/s12920-021-01143-2
   PubMed Web of Science ®Google Scholar
• Lin Y, Huang J, Zhu Z, et al. Overlap phenotypes of the left ventricular noncompaction and hypertrophic cardiomyopathy with complex arrhythmias and heart failure induced by the novel truncated DSC2 mutation. Orphanet J Rare Diseases. 2021;16(1):1–33. doi: 10.1186/s13023-021-02112-9
   PubMed Web of Science ®Google Scholar
• Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013;45(9):1044–1049. doi: 10.1038/ng.2712
   PubMed Web of Science ®Google Scholar
• Hosseini SM, Kim R, Udupa S, et al. Reappraisal of reported genes for sudden arrhythmic death. Circulation. 2018;138(12):1195–1205. doi: 10.1161/CIRCULATIONAHA.118.035070
   PubMed Web of Science ®Google Scholar
• Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7(1):33–46. doi: 10.1016/j.hrthm.2009.09.069
   PubMed Web of Science ®Google Scholar
• Gray B, Bagnall RD, Lam L, et al. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016;13(8):1652–1660. doi: 10.1016/j.hrthm.2016.05.004
   PubMed Web of Science ®Google Scholar
• Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–1963. doi: 10.1016/j.hrthm.2013.05.014
   PubMed Web of Science ®Google Scholar
• Sturm AC, Knowles JW, Gidding SS, et al. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72(6):662–680. doi: 10.1016/j.jacc.2018.05.044
   PubMed Web of Science ®Google Scholar
• Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578–2589. doi: 10.1016/j.jacc.2016.03.520
   PubMed Web of Science ®Google Scholar
• Renard M, Francis C, Ghosh R, et al. Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2018;72(6):605–615. doi: 10.1016/j.jacc.2018.04.089
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–157. doi: 10.1038/s41586-019-1711-4
   PubMed Web of Science ®Google Scholar
• Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161–177. doi: 10.1038/s41576-022-00541-1
   PubMed Web of Science ®Google Scholar
• Banskota S, Raguram A, Suh S, et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell. 2022;185(2):250–265. doi: 10.1016/j.cell.2021.12.021
   PubMed Web of Science ®Google Scholar
• Hansen S, McClements ME, Corydon TJ, et al. Future perspectives of prime editing for the treatment of inherited retinal diseases. Cells. 2023;12(3):440. doi: 10.3390/cells12030440
   PubMed Web of Science ®Google Scholar
• Gao P, Lyu Q, Ghanam AR, et al. Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression. Genome Bio. 2021;22(1):1–21. doi: 10.1186/s13059-021-02304-3
   PubMed Web of Science ®Google Scholar
• Doman JL, Pandey S, Neugebauer ME, et al. Phage-assisted evolution and protein engineering yield compact, efficient prime editors. Cell. 2023;186(18):3983–4002. doi: 10.1016/j.cell.2023.07.039
   PubMed Web of Science ®Google Scholar
• Nelson JW, Randolph PB, Shen SP, et al. Engineered pegRnas improve prime editing efficiency. Nature Biotechnol. 2022;40(3):402–410. doi: 10.1038/s41587-021-01039-7
   PubMed Web of Science ®Google Scholar
• Zhao Z, Shang P, Mohanraju P, et al. Prime editing: advances and therapeutic applications. Trends Biotechnol. 2023;41(8):1000–1012. doi: 10.1016/j.tibtech.2023.03.004
   PubMed Web of Science ®Google Scholar
• Happi Mbakam C, Rousseau J, Lu Y, et al. Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene. Mol Ther Nucleic Acids. 2022;30:272–285. doi: 10.1016/j.omtn.2022.09.022
   PubMedGoogle Scholar
• Xu Z, Ma D, Su H, et al. Explore the dominant factor in prime editing via a view of DNA processing. Synth Syst Biotechnol. 2023;8(3):371–377. doi: 10.1016/j.synbio.2023.05.007
   PubMed Web of Science ®Google Scholar
• Liu N, Zhou L, Lin G, et al. HDAC inhibitors improve CRISPR-Cas9 mediated prime editing and base editing. Mol Ther Nucleic Acids. 2022;29:36–46. doi: 10.1016/j.omtn.2022.05.036
   PubMedGoogle Scholar
• Zhang G, Liu Y, Huang S, et al. Enhancement of prime editing via xrRNA motif-joined pegRNA. Nat Commun. 2022;13(1):1856. doi: 10.1038/s41467-022-29507-x
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Sun W, et al. Enhancing prime editing efficiency by modified pegRNA with RNA G-quadruplexes. J Mol Cell Biol. 2022;14(4):mjac022. doi: 10.1093/jmcb/mjac022
   PubMed Web of Science ®Google Scholar
• Li X, Zhou L, Gao BQ, et al. Highly efficient prime editing by introducing same-sense mutations in pegRNA or stabilizing its structure. Nat Commun. 2022;13(1):1669. doi: 10.1038/s41467-022-29339-9
   PubMed Web of Science ®Google Scholar
• Schene IF, Joore IP, Oka R, et al. Prime editing for functional repair in patient-derived disease models. Nat Commun. 2020;11(1):5352. doi: 10.1038/s41467-020-19136-7
   PubMed Web of Science ®Google Scholar
• Choi J, Chen W, Suiter CC, et al. Precise genomic deletions using paired prime editing. Nat Biotechnol. 2022;40(2):218–226. doi: 10.1038/s41587-021-01025-z
   PubMed Web of Science ®Google Scholar
• Anzalone AV, Gao XD, Podracky CJ, et al. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nature Biotechnol. 2022;40(5):731–740. doi: 10.1038/s41587-021-01133-w
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Liu J, Wu H, et al. Increasing the efficiency and precision of prime editing with guide RNA pairs. Nat Chem Biol. 2022;18(1):29–37. doi: 10.1038/s41589-021-00889-1
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhang X-O, Weng Z, et al. Deletion and replacement of long genomic sequences using prime editing. Nat Biotechnology. 2022;40(2):227–234. doi: 10.1038/s41587-021-01026-y
   PubMed Web of Science ®Google Scholar
• Zaidi S, Brueckner M. Genetics and genomics of congenital heart disease. Circ Res. 2017;120(6):923–940. doi: 10.1161/CIRCRESAHA.116.309140
   PubMed Web of Science ®Google Scholar
• Liu N, Olson EN. CRISPR modeling and correction of cardiovascular disease. Circ Res. 2022;130(12):1827–1850. doi: 10.1161/CIRCRESAHA.122.320496
   PubMed Web of Science ®Google Scholar
• Kyriakopoulou E, Monnikhof T, van Rooij E. Gene editing innovations and their applications in cardiomyopathy research. Dis Model Mech. 2023;16(5). doi: 10.1242/dmm.050088
   PubMed Web of Science ®Google Scholar
• Ma S, Jiang W, Liu X, et al. Efficient correction of a hypertrophic cardiomyopathy mutation by ABEmax-NG. Circ Res. 2021;129(10):895–908. doi: 10.1161/CIRCRESAHA.120.318674
   PubMed Web of Science ®Google Scholar
• Chemello F, Chai AC, Li H, et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv. 2021;7(18):eabg4910. doi: 10.1126/sciadv.abg4910
   PubMed Web of Science ®Google Scholar
• Lee RG, Mazzola, AM. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. Circulation. 202317;147(3):242–253. doi: 10.1161/CIRCULATIONAHA.122.062132
   PubMed Web of Science ®Google Scholar
• Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429–434. doi: 10.1038/s41586-021-03534-y
   PubMed Web of Science ®Google Scholar
• Zuo Y, Zhang C, Zhou Y, et al. Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice. Cell Biosci. 2023;13(1):109. doi: 10.1186/s13578-023-01036-0
   PubMed Web of Science ®Google Scholar
• Chai AC, Cui M, Chemello F, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023;29(2):401–411. doi: 10.1038/s41591-022-02176-5
   PubMed Web of Science ®Google Scholar
• Reichart D, Newby GA, Wakimoto H, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nature Med. 2023;29(2):412–421. doi: 10.1038/s41591-022-02190-7
   PubMed Web of Science ®Google Scholar
• Nishimasu H, Shi X, Ishiguro S, et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Sci (1979). 2018;361(6408):1259–1262. doi: 10.1126/science.aas9129
   Web of Science ®Google Scholar
• Wu WY, Mohanraju P, Liao C, et al. The miniature CRISPR-Cas12m effector binds DNA to block transcription. Molecular Cell. 2022;82(23):4487–4502. e7. doi: 10.1016/j.molcel.2022.11.003
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Zhang Y, Cui M, et al. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci, Trans Med. 2022;14(672):eade1633. doi: 10.1126/scitranslmed.ade1633
   PubMed Web of Science ®Google Scholar
• Sürün D, Schneider A, Mircetic J, et al. Efficient generation and correction of mutations in human iPS cells utilizing mRnas of CRISPR base editors and prime editors. Genes (Basel). 2020;11(5):511. doi: 10.3390/genes11050511
   PubMed Web of Science ®Google Scholar
• Godbout K, Tremblay JP. Prime editing for human gene therapy: where are we Now? Cells. 2023;12(4):536. doi: 10.3390/cells12040536
   PubMed Web of Science ®Google Scholar
• Li H, Busquets O, Verma Y, et al. Highly efficient generation of isogenic pluripotent stem cell models using prime editing. Elife. 2022;11:e79208. doi: 10.7554/eLife.79208
   PubMed Web of Science ®Google Scholar
• Davis JR, Banskota S, Levy JM, et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat Biotechnol. 2023;42:1–12.
   Web of Science ®Google Scholar
• Dave J, Raad N, Mittal N, et al. Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact. Cardiovasc Res. 2022;118(15):3140–3150. doi: 10.1093/cvr/cvac021
   PubMed Web of Science ®Google Scholar
• Zhou M, Tang S, Duan N, et al. Targeted-deletion of a tiny sequence via prime editing to restore SMN expression. Int J Mol Sci. 2022;23(14):7941. doi: 10.3390/ijms23147941
   PubMed Web of Science ®Google Scholar
• Happi Mbakam C, Rousseau J, Tremblay G, et al. Prime editing permits the introduction of specific mutations in the gene responsible for Duchenne muscular dystrophy. Int J Mol Sci. 2022;23(11):6160. doi: 10.3390/ijms23116160
   PubMed Web of Science ®Google Scholar
• Nishiga M, Qi LS, Wu JC. Therapeutic genome editing in cardiovascular diseases. Adv Drug Deliv Rev. 2021;168:147–157.
   PubMed Web of Science ®Google Scholar
• Li Z-H, Wang J, Xu J-P, et al. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. Mil Med Res. 2023;10(1):12. doi: 10.1186/s40779-023-00447-x
   PubMed Web of Science ®Google Scholar
• Zhi S, Chen Y, Wu G, et al. Dual-AAV delivering split prime editor system for in vivo genome editing. Mol Ther. 2022;30(1):283–294. doi: 10.1016/j.ymthe.2021.07.011
   PubMed Web of Science ®Google Scholar
• Hernandez-Benitez R, Martinez-Martinez ML, Lajara J, et al. At the heart of genome editing and cardiovascular diseases. Circ Res. 2018;123(2):221–223. doi: 10.1161/CIRCRESAHA.118.312676
   PubMed Web of Science ®Google Scholar
• Lázár E, Sadek HA, Bergmann O. Cardiomyocyte renewal in the human heart: insights from the fall-out. Eur Heart J. 2017;38(30):2333–2342. doi: 10.1093/eurheartj/ehx343
   PubMed Web of Science ®Google Scholar
• Young A, Bradley LA, Wolf MJ. In vivo methods to monitor cardiomyocyte proliferation. J Cardiovasc Dev Dis. 2022;9(3):73. doi: 10.3390/jcdd9030073
   PubMed Web of Science ®Google Scholar
• Hakim CH, Kumar SRP, Pérez-López DO, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12(1):6769. doi: 10.1038/s41467-021-26830-7
   PubMed Web of Science ®Google Scholar
• Marino ND, Pinilla-Redondo R, Csörgő B, et al. Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies. Nat Methods. 2020;17(5):471–479. doi: 10.1038/s41592-020-0771-6
   PubMed Web of Science ®Google Scholar
• Wei CT, Popp NA, Peleg O, et al. A chemically controlled Cas9 switch enables temporal modulation of diverse effectors. Nat Chem Biol. 2023;19(8):1–11.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu J, Janssen JM, et al. Broadening the reach and investigating the potential of prime editors through fully viral gene-deleted adenoviral vector delivery. Nucleic Acids Res. 2021;49(20):11986–12001. doi: 10.1093/nar/gkab938
   PubMed Web of Science ®Google Scholar
• Rutanen J, Rissanen TT, Markkanen JE, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation. 2004;109(8):1029–1035. doi: 10.1161/01.CIR.0000115519.03688.A2
   PubMed Web of Science ®Google Scholar
• Leikas AJ, Hassinen I, Hedman A, et al. Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy eight-year follow-up of phase I KAT301 study. Genet Ther. 2022;29(5):289–293. doi: 10.1038/s41434-021-00295-1
   PubMed Web of Science ®Google Scholar
• Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR/Cas: current state and perspectives. Viruses. 2021;13(7):1288. doi: 10.3390/v13071288
   PubMed Web of Science ®Google Scholar
• Wang J, Yu L, Zhou A, et al. Non-viral gene delivery systems for treatment of myocardial infarction: targeting strategies and cardiac cell modulation. Pharmaceutics. 2021;13(9):1520. doi: 10.3390/pharmaceutics13091520
   PubMed Web of Science ®Google Scholar
• Dirkx N, Weuring WJ, De Vriendt E, et al. Increased prime edit rates in KCNQ2 and SCN1A via single nicking all-in-one plasmids. BMC Biol. 2023;21(1):156. doi: 10.1186/s12915-023-01646-7
   PubMed Web of Science ®Google Scholar
• Hughes TS, Langer SJ, Virtanen SI, et al. Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression. J Gene Med. 2009;11(9):782–790. doi: 10.1002/jgm.1364
   PubMed Web of Science ®Google Scholar
• Navarro RS, de Paiva Narciso N, Gilchrist A, et al. Abstract 11376: catheter-injectable hydrogel for the delivery of a minicircle encoding SDF-la as therapy for myocardial infarction. Circulation. 2022;146(Suppl_1):A11376. doi: 10.1161/circ.146.suppl_1.11376
   Google Scholar
• Qiu M, Glass Z, Xu Q. Nonviral nanoparticles for CRISPR-based genome editing: is it just a simple adaption of what have been developed for nucleic acid delivery? Biomacromolecules. 2019;20(9):3333–3339. doi: 10.1021/acs.biomac.9b00783
   PubMed Web of Science ®Google Scholar
• Rousseau B. Engineering virus-like particles for the delivery of genome editing enzymes. 2022.
   Google Scholar
• Yuan Q, Gao X. Multiplex base-and prime-editing with drive-and-process CRISPR arrays. Nat Commun. 2022;13(1):2771. doi: 10.1038/s41467-022-30514-1
   PubMed Web of Science ®Google Scholar
• Koblan LW, Erdos MR, Wilson C, et al. In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice. Nature. 2021;589(7843):608–614. doi: 10.1038/s41586-020-03086-7
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang C, Li H, et al. Efficient precise in vivo base editing in adult dystrophic mice. Nat Commun. 2021;12(1):3719. doi: 10.1038/s41467-021-23996-y
   PubMed Web of Science ®Google Scholar
• McClements ME, MacLaren RE. Focus: genome editing: adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes. Yale J Biol Med. 2017;90(4):611.
   PubMed Web of Science ®Google Scholar
• Zhou J, Ren Z, Xu J, et al. Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives. Medical Review. 2021;1(1):6–9. doi: 10.1515/mr-2021-0010
   Google Scholar
• Ylä-Herttuala S, Baker AH. Cardiovascular gene therapy: past, present, and future. Mol Ther. 2017;25(5):1095–1106. doi: 10.1016/j.ymthe.2017.03.027
   PubMed Web of Science ®Google Scholar
• Kok CY, MacLean LM, Ho JC, et al. Potential applications for targeted gene therapy to protect against Anthracycline Cardiotoxicity: JACC: cardiooncology primer. JACC Cardio Oncology. 2021;3(5):650–662. doi: 10.1016/j.jaccao.2021.09.008
   PubMedGoogle Scholar
• Skopenkova VV, Egorova TV, Bardina MV. Muscle-specific promoters for gene therapy. Acta Naturae. 2021;13(1):47. doi: 10.32607/actanaturae.11063
   PubMed Web of Science ®Google Scholar
• Korpela H, Järveläinen N, Siimes S, et al. Gene therapy for ischaemic heart disease and heart failure. J Intern Med. 2021;290(3):567–582. doi: 10.1111/joim.13308
   PubMed Web of Science ®Google Scholar
• Zhuo C, Zhang J, Lee JH, et al. Spatiotemporal control of CRISPR/Cas9 gene editing. Signal Transduction Target Therapy. 2021;6(1):238. doi: 10.1038/s41392-021-00645-w
   PubMed Web of Science ®Google Scholar
• Crudele JM, Chamberlain JS. Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat Commun. 2018;9(1):3497. doi: 10.1038/s41467-018-05843-9
   PubMedGoogle Scholar
• Moore OM, Ho KS, Copeland JS, et al. Genome editing and cardiac arrhythmias. Cells. 2023;12(10):1363. doi: 10.3390/cells12101363
   PubMed Web of Science ®Google Scholar
• Lebek S, Chemello F, Caravia XM, et al. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Sci (1979). 2023;379(6625):179–185. doi: 10.1126/science.ade1105
   Google Scholar
• Bharucha N, Arias A, Karakikes I. The potential of CRISPR-Cas9 prime editing for cardiovascular disease research and therapy. Curr Opin Cardiol. 2022;379(5):413–418. doi: 10.1097/HCO.0000000000000985
   Google Scholar